Drug intelligence / Profile preview

CRISPR-Cas9 CXCL10 knockout

Development stage
Preclinical
Lead developer
University of Alabama at Birmingham
Modality
CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
01

Overview

CRISPR-Cas9 CXCL10 knockout refers to the targeted genetic deletion of the C-X-C motif chemokine ligand 10 (CXCL10) gene using the CRISPR-Cas9 gene-editing system. In the context of T-cell acute lymphoblastic leukemia (T-ALL) research, this modification is employed to investigate the role of the CXCR3/CXCL10 signaling axis in central nervous system (CNS) and meningeal infiltration. CXCL10 is primarily expressed by meningeal stromal cells in response to inflammatory cytokines (such as IFN-gamma and TNF) produced by infiltrating T-ALL cells. By knocking out CXCL10 in stromal cells or utilizing CXCL10-deficient mouse models, researchers have demonstrated a significant reduction in leukemic cell adhesion and migration to the meninges. This suggests that targeting the CXCL10 chemokine or its receptor, CXCR3, could be a viable therapeutic strategy to prevent or treat CNS involvement and relapse in T-ALL patients.

Other names
CXCL10 knockoutCXCL-10 knockoutCXCL 10 knockoutCXCL10 KOCXCL-10 KOCXCL 10 KO
02

Targets

CXCL10 (C-X-C Motif Chemokine Ligand 10)

Beyond the preview

Go deeper on CRISPR-Cas9 CXCL10 knockout.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRISPR-Cas9 CXCL10 knockout.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call